Chronic use of Tesamorelin (a stabilized 44-amino-acid GHRH analog) or other GH-releasing peptides produces a cascade that is far more selective—and ultimately more self-limiting—than the classical picture of pituitary shutdown seen with high-dose rhGH. Across the excerpts the same sequence is described: peptide-driven GH pulses → rapid rise in IGF-1 → progressive fall in both basal and stimulated GH within 3–6 months, even though the medication is continued. Peptide Protocols Vol. 1 summarizes the clinical outcome most bluntly: “after 12–18 wk of nightly Tesamorelin the mean 24-h GH AUC falls back toward baseline despite full adherence, and IGF-1 plateaus 20–30 % above pre-treatment values instead of continuing to climb.” The texts agree that this is not classical tachyphylaxis; rather, it is a negative-feedback reset point. Persistent IGF-1 elevation feeds back on both hypothalamic GHRH neurons and pituitary somatotrophs, so endogenous GHRH release and residual peptide efficacy are simultaneously damped. The result is a new equilibrium in which the patient is partially GH-deficient off-drug but only modestly GH-sufficient on-drug—a hormonal “half-way house.”
Down-stream hormonal consequences of this reset are spelled out in several sources. Grow Young with HGH (chapters 15 & 21) reports that once IGF-1 stabilizes, insulin sensitivity first improves (visceral fat loss lowers fasting insulin ~25 %), but after 9–12 months the same cohort shows a 15–20 % rise in fasting insulin and a 0.4–0.6 % increase in HbA1c, despite unchanged body weight. The interpretation offered is that chronic IGF-1 signaling eventually induces SOCS-2 and SOCS-3 in liver and muscle, blunting the insulin receptor pathway—an example of GH/IGF-1 crosstalk turning from friendly to hostile. The adrenal axis is also pulled into the picture: the same volume cites a Swedish series in which 24-h urinary free cortisol rose 30 % after 6 months of continuous GHRP-2, accompanied by a measurable fall in morning DHEA-S. The proposed mechanism is not direct pituitary suppression but rather IGF-1-mediated potentiation of adrenal 17,20-lyase activity, shunting pregnenolone toward cortisol at the expense of androgen synthesis. Thus the “anabolic” peptide program quietly tilts the glucocorticoid/androgen ratio in the opposite direction.
Thyroid function receives less attention, but Handbook of Biologically Active Peptides (chronobiology section) notes that nightly GH surges lower nocturnal TSH by 15–25 % and drop T3 by 8–12 % within 8 wk, probably via somatostatin up-regulation; these values revert when the peptide is stopped, but the data stop at 12 months, so whether a secondary hypothyroid phenotype emerges with multi-year use is unanswered. Prolactin is repeatedly described as “largely unaffected” by Tesamorelin, whereas non-selective GHRPs such as ipamorelin or hexarelin can double prolactin in the first month; even here, tolerance develops and values drift back toward baseline, but the early surge can precipitate gynecomastia in susceptible males. Finally, gonadal axes are touched on only anecdotally: Grow Young with HGH mentions two post-menopausal women whose hot-flashes diminished and FSH fell from 60 to 8 IU/L during 6 months of low-dose rhGH, implying a pseudo-rejuvenation of the hypothalamic pulse generator; whether this represents a true steroid increase or simply better thermoregulation is not clarified, and no corresponding male testosterone data are given.
The most counter-intuitive finding is the inversion of the insulin story: peptides marketed to “reverse metabolic syndrome” actually re-create it if continued beyond a year, a trajectory documented in both Peptide Protocols and Grow Young with HGH. The practical corollary—almost never stated in the marketing literature—is that cyclical or pulsed regimens (e.g., 5 nights on / 2 nights off, or 3-month blocks with 1-month washout) may be mandatory to prevent the SOCS-mediated insulin resistance that otherwise cancels the initial visceral-fat benefit.
Critical gaps are obvious. No source provides longitudinal data past 24 months, so the possibility of further pituitary atrophy, clinically relevant adrenal suppression, or thyroid failure remains speculative. There is also outright disagreement on cancer risk: The Future of Aging argues that the modest IGF-1 elevation is “probably neutralized by improved immune surveillance,” whereas Peptide Protocols concedes “theoretical concern for microscopic tumor progression” but cites no human event rates. Finally, none of the books quantify recovery time: how long it takes for the GH axis to re-awaken after cessation, or whether repeated cycles eventually blunt the rebound altogether.
References
- Effect of short peptides on neuronal differentiation of stem — Sergio Caputi
- Grow young with HGH _ the amazing medically proven plan to
- Handbook of Biologically Active Peptides
- Peptide Protocols Volume One — William A Seeds MD
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- The future of aging pathways to human life extension — Ray Kurzweil
- Terry Grossman (auth )
- Gregory M Fahy
- Dr, s10522-010-9307-2